A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
NCT02395601 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41
Last updated 2022-05-18
Summary
First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.
Conditions
Interventions
- DRUG
-
CPI-1205
Small molecule inhibitor of the enzyme EZH2
Sponsors & Collaborators
-
Constellation Pharmaceuticals
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-03-31
- Primary Completion
- 2018-12-31
- Completion
- 2018-12-31
Countries
- United States
Study Locations
More Related Trials
-
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
NCT05113069 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
NCT05828589 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
NCT03719560 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019 ·Status: RECRUITING ·Phase: PHASE1
-
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
NCT03145064 ·Status: COMPLETED ·Phase: PHASE2
-
A Study for Participants With Advanced Cancer
NCT01214629 ·Status: COMPLETED ·Phase: PHASE1
-
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
NCT01959698 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
NCT00412997 ·Status: COMPLETED ·Phase: PHASE1
-
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
NCT05887726 ·Status: UNKNOWN ·Phase: PHASE2
-
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
NCT06594432 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Erythropoietin for Management of Anemia Caused by Chemotherapy
NCT02890602 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
NCT01238692 ·Status: COMPLETED ·Phase: PHASE2
-
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
NCT04668365 ·Status: SUSPENDED ·Phase: PHASE2
-
Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma
NCT04183569 ·Status: UNKNOWN
-
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
NCT05200312 ·Status: UNKNOWN ·Phase: PHASE2
-
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
NCT01226849 ·Status: COMPLETED ·Phase: PHASE1
-
SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
NCT07347288 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL
NCT02342665 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
NCT02660710 ·Status: COMPLETED ·Phase: PHASE2
-
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
NCT03220022 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Treatment of Localized Low Grade Lymphomas
NCT00536458 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
NCT05206357 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
NCT05596097 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05875428 ·Status: UNKNOWN ·Phase: PHASE2